M&A Deal Summary |
|
|---|---|
| Date | 2025-12-10 |
| Target | Pharmathen - Ophthalmology Business |
| Sector | Life Science |
| Buyer(s) | NTC |
| Sellers(s) | Pharmathen |
| Deal Type | Divestiture |
SEARCH BY
NTC is a pharmaceutical company operating in the fields of generic drugs, devices doctors, and nutraceuticals. NTC is based in Milan, Italy.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: Netherlands M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1969 |
| Sector | Life Science |
| Employees | 1,000 |
| Revenue | 180M EUR (2014) |
Pharmathen is a European pharmaceutical company that focuses on developing, manufacturing, and out-licensing complex generic pharmaceutical products. Pharmathen's differentiated B2B model attracts a blue-chip customer base of more than 215 generic pharmaceutical companies, which it serves from two US/EU-approved manufacturing facilities in Greece. Pharmathen was founded in 1969 and is based in Amstelveen, Netherlands.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: Netherlands M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
